353 related articles for article (PubMed ID: 37402345)
1. Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS.
Xu Q; Yang X; Qiu Z; Li D; Wang H; Ye H; Jiao L; Zhang J; Di L; Lei P; Dong H; Liu Z
Mult Scler Relat Disord; 2023 Sep; 77():104797. PubMed ID: 37402345
[TBL] [Abstract][Full Text] [Related]
2. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis.
Molazadeh N; Akaishi T; Bose G; Nishiyama S; Chitnis T; Levy M
Mult Scler Relat Disord; 2023 Dec; 80():105093. PubMed ID: 37949025
[TBL] [Abstract][Full Text] [Related]
3. Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS.
Banks SA; Morris PP; Chen JJ; Pittock SJ; Sechi E; Kunchok A; Tillema JM; Fryer JP; Weinshenker BG; Krecke KN; Lopez-Chiriboga AS; Nguyen A; Greenwood TM; Lucchinetti CF; Zalewski NL; Messina SA; Flanagan EP
J Neurol Neurosurg Psychiatry; 2020 Dec; ():. PubMed ID: 33372052
[TBL] [Abstract][Full Text] [Related]
4. Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
Cacciaguerra L; Morris P; Tobin WO; Chen JJ; Banks SA; Elsbernd P; Redenbaugh V; Tillema JM; Montini F; Sechi E; Lopez-Chiriboga AS; Zalewski N; Guo Y; Rocca MA; Filippi M; Pittock SJ; Lucchinetti CF; Flanagan EP
Neurology; 2023 Mar; 100(13):e1418-e1432. PubMed ID: 36690455
[TBL] [Abstract][Full Text] [Related]
5. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
[TBL] [Abstract][Full Text] [Related]
6. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
7. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
Barreras P; Vasileiou ES; Filippatou AG; Fitzgerald KC; Levy M; Pardo CA; Newsome SD; Mowry EM; Calabresi PA; Sotirchos ES
Neurology; 2022 Nov; 99(22):e2504-e2516. PubMed ID: 36240094
[TBL] [Abstract][Full Text] [Related]
8. Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum Disorder.
Goldman-Yassen A; Lee A; Gombolay G
Pediatr Neurol; 2024 Apr; 153():125-130. PubMed ID: 38382244
[TBL] [Abstract][Full Text] [Related]
9. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
[TBL] [Abstract][Full Text] [Related]
11. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
12. Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder.
Cho EB; Min JH; Waters P; Jeon M; Ju ES; Kim HJ; Kim SH; Shin HY; Kang SY; Lim YM; Oh SY; Lee HL; Sohn E; Lee SS; Oh J; Kim S; Huh SY; Cho JY; Seok JM; Kim BJ; Kim BJ
Front Immunol; 2024; 15():1320094. PubMed ID: 38576611
[TBL] [Abstract][Full Text] [Related]
13. Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS.
Redenbaugh V; Chia NH; Cacciaguerra L; McCombe JA; Tillema JM; Chen JJ; Lopez Chiriboga AS; Sechi E; Hacohen Y; Pittock SJ; Flanagan EP
Mult Scler; 2023 Jun; 29(7):799-808. PubMed ID: 37218499
[TBL] [Abstract][Full Text] [Related]
14. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Bauer A; Rudzki D; Berek K; Dinoto A; Lechner C; Wendel EM; Hegen H; Deisenhammer F; Berger T; Höftberger R; Rostasy K; Mariotto S; Reindl M
Front Immunol; 2022; 13():1037812. PubMed ID: 36451827
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.
Redenbaugh V; Flanagan EP
Neurotherapeutics; 2022 Apr; 19(3):808-822. PubMed ID: 35267170
[TBL] [Abstract][Full Text] [Related]
16. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.
Duan Y; Zhuo Z; Li H; Tian DC; Li Y; Yang L; Gao C; Zhang T; Zhang X; Shi FD; Barkhof F; Liu Y
J Neurol Neurosurg Psychiatry; 2021 Jul; 92(7):709-716. PubMed ID: 33687975
[TBL] [Abstract][Full Text] [Related]
17. Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis.
Stiebel-Kalish H; Rubarth K; Shouchane-Blum K; Tiosano A; Lotan I; Hellmann MA; Wilf-Yarkoni A; Bialer O; Flanagan EP; Pittock SJ; Bhatti MT; Schmitz-Hübsch T; Paul F; Asseyer S; Chen JJ
Sci Rep; 2022 Dec; 12(1):21312. PubMed ID: 36494385
[TBL] [Abstract][Full Text] [Related]
18. Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD.
Duchow A; Bellmann-Strobl J; Friede T; Aktas O; Angstwurm K; Ayzenberg I; Berthele A; Dawin E; Engels D; Fischer K; Flaskamp M; Giglhuber K; Grothe M; Havla J; Hümmert MW; Jarius S; Kaste M; Kern P; Kleiter I; Klotz L; Korporal-Kuhnke M; Kraemer M; Krumbholz M; Kümpfel T; Lohmann L; Ringelstein M; Rommer P; Schindler P; Schubert C; Schwake C; Senel M; Then Bergh F; Tkachenko D; Tumani H; Trebst C; Vardakas I; Walter A; Warnke C; Weber MS; Wickel J; Wildemann B; Winkelmann A; Paul F; Stellmann JP; Häußler V;
Ann Neurol; 2024 Apr; 95(4):720-732. PubMed ID: 38086777
[TBL] [Abstract][Full Text] [Related]
19. The distinction of area postrema syndrome between MOGAD and NMOSD.
Chen Y; Zhangbao J; Xu J; Zhou L; Zhou Z; Quan C
Heliyon; 2024 May; 10(10):e30633. PubMed ID: 38779012
[TBL] [Abstract][Full Text] [Related]
20. Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis.
Chia NH; Redenbaugh V; Chen JJ; Pittock SJ; Flanagan EP
Mult Scler; 2023 May; 29(6):748-752. PubMed ID: 36691800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
